Mod­er­na and CARs­gen team up on CAR-T cell ther­a­py and mR­NA can­cer vac­cine com­bo

CARs­gen will test its Claudin18.2 CAR T-cell can­di­date, dubbed CT041, in com­bi­na­tion with Mod­er­na’s in­ves­ti­ga­tion­al mR­NA can­cer vac­cine in a col­lab­o­ra­tion be­tween the two com­pa­nies.

As part of the col­lab­o­ra­tion, the two can­di­dates will be in­ves­ti­gat­ed in pre­clin­i­cal and Phase I stud­ies. Mod­er­na’s can­cer vac­cine is de­signed around the Claudin18.2 pro­tein.

CARs­gen is al­ready in­ves­ti­gat­ing CT041 in gas­tric, pan­cre­at­ic and oth­er di­ges­tive sys­tem can­cers in sev­er­al tri­als in Chi­na and North Amer­i­ca. Ac­cord­ing to CARS­gen, CT041 is the “most ad­vanced” sol­id tu­mor CAR-T in de­vel­op­ment, as it is in sev­er­al Phase I and II tri­als. It was grant­ed an or­phan drug des­ig­na­tion from the FDA in 2020 and re­gen­er­a­tive med­i­cine ad­vanced ther­a­py des­ig­na­tion in 2022.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER